AnaCardio successfully completes first part of AC01 HFrEF study and provides a clinical update
Stockholm, Sweden, September 17, 2024 AnaCardio, a Swedish clinical-stage biopharmaceutical company developing novel contractile agents to treat patients with heart failure, today announced that the clinical conduct of the first part of its GOAL-HF1 study in patients with heart failure and reduced ejection fraction (HFrEF) has been completed. Part A of GOAL-HF1 is a randomized, […]